Riskpilot← Back to searchSign inGet full accessNordblom Läkarkonsult AB
ABActiveOrg 5590383450Odengatan 26General medical practice activities · NACE 8621Est. 20151 employees
Revenue 2024
SEK 14K
-92% vs 2023
EBITDA margin
47.9%
+559% vs 2023
Equity ratio
10.3%
Financial strength
Net profit 2024
SEK -18K
+44% vs 2023
| Revenue | SEK 14K | -92% |
| EBITDA | SEK 7K | +559% |
| Net profit | SEK -18K | +44% |
| Total assets | SEK 76K | -24% |
| Equity | SEK 8K | -70% |
| Employees | 1 | — |
Legal name
Nordblom Läkarkonsult AB
Org number
5590383450
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
2 december 2015
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är konsultverksamhet inom sjukvård, författarverksamhet inom sjukvård och skönlitteratur och därmed förenlig verksamhet.
Address
Odengatan 26
Email
jonathan.nordblom@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 426 | 1 649 | 337 | 173 | 14 |
| Staff expenses | — | −955 | −129 | −71 | −3 |
| EBITDA | 857 | 53 | −113 | −2 | 7 |
| Depreciation & amort. | −16 | −31 | −35 | −25 | −25 |
| EBIT | 841 | 22 | −148 | −26 | −18 |
| Net financials | — | −21 | −22 | −6 | −0 |
| Profit before tax | 819 | 11 | −157 | −32 | −18 |
| Tax | −130 | −10 | — | — | — |
| Net profit | 689 | 1 | −157 | −32 | −18 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 376 | 818 | 259 | 100 | 76 |
| Equity | 564 | 265 | 58 | 26 | 8 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 791 | 541 | 201 | 75 | 68 |
| Total debt | 791 | 541 | 201 | 75 | 68 |
EBITDA margin
47.9%
This company
15.8%
Market median
+203% vs market
20202024
Equity ratio
10.3%
This company
38.2%
Market median
-73% vs market
20202024
Return on equity
-228.3%
This company
18.4%
Market median
-1341% vs market
20202024
Net profit margin
-123.8%
This company
8.1%
Market median
-1628% vs market
20202024
Asset turnover
0.19×
This company
1.12×
Market median
-83% vs market
20202024
Debt / equity
8.72×
This company
0.62×
Market median
-1306% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nordblom Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sarah Charlott Nordblom | Deputy Board Member | 0 companies |
| Jonathan Lars Nordblom | Board of Directors | 0 companies |